Veriheal

MAY 12, 2021

In light of such, and the fact that cancer is a common qualifying condition for cannabis, this research team took to expanding the available basic information on cannabis in the cancer population in order to provide clinical trial designers with better information needed for planned studies.

Patients 98

Patients Consumption Clinical Trials Education 98

Veriheal

MAY 26, 2022

Patients around the world are in need of natural, alternative medical solutions, and Realm of Caring (RoC) is on a mission to serve them. RoC also works to increase patients’ access to medical cannabis by helping U.S. To date, Veriheal’s global team has helped hundreds of thousands of patients gain access to medical cannabis.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

The Cannigma

FEBRUARY 2, 2021

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition. Patients can also access CBD products without a prescription through local pharmacies.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

MMJ Recs

MAY 9, 2024

As such, we provide you with a comprehensive guide for veterans using medical cannabis and the various aspects of it, including its usage, accessibility, legal considerations, healthcare options, and available resources. Navigating the complexities surrounding the Veterans Administration and medical cannabis can be daunting.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? In fact, from pediatricians to geriatricians, I cannot think of any medical practitioner that does not need to be well informed about the endocannabinoid system and cannabis-based therapeutics. million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

AUGUST 7, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable, and accessible work environment. European Regulatory Lead Executive Summary. Key Responsibilities.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

MMJ Recs

JUNE 15, 2022

The best pain management physicians collaborate with the patient to develop a treatment regimen that works best for them as an individual. They offer top-rated doctors and pain relief specialists that work with each patient to develop a treatment plan tailored to their specific needs. Unique Pain Medicine.

Patients 52

Patients Treatment Clinical Trials Therapy 52

Otherside Farms

JANUARY 25, 2019

A medical marijuana patient in Los Angeles with inoperable liver cancer has been removed from Cedars-Sinai Medical Center’s transplant list after testing positive for marijuana. Sixty-three-year-old medical marijuana patient Norman B. The letter also urges Cedars-Sinai to change its transplant eligibility policy. Dr. Steven D.

Patients 76

Patients Clinical Trials Marijuana Policy 76

Cannabis Law Report

JUNE 21, 2021

RYAH publishes monthly reports discussing various topics arising from their analysis of the reams of data in its proprietary RYAH Cloud database, offering a glimpse of how the information can be used. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. Advantages of Data, Macro, and Micro.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

JUNE 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. The goal at TrPR is to accelerate progress towards impactful and accessible psychedelic treatments.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. CBD Oil for Medical Conditions CBD oil has gained popularity as a versatile and accessible option for managing various medical conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Veriheal

FEBRUARY 9, 2023

A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. All imaging and behavioral data will be accessible to the public after the study is complete. What Is an MRI? Magic Mushrooms: The Ticket to a Stress-Free MRI?

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. Availability of other information about COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Veriheal

DECEMBER 21, 2022

attorney general 60 days to either approve a given application or request supplemental information from the marijuana research applicant. While both options seem better than the current situation, they could actually make it more difficult to access. 8454, the “Medical Marijuana and Cannabidiol Research Expansion Act,” has been passed.

Clinical Trials 98

Clinical Trials Marijuana Decriminalization History 98

Cannabis Law Report

AUGUST 19, 2019

There have been more than 7,500 approvals for medicinal cannabis in Australia since legalisation in 2016 – so why don’t we know if it is helping patients? Access to medicinal cannabis for patients was legalised in Australia in 2016, allowing doctors to request permission to prescribe from the Australian government.

Medicine 45

Medicine Patients Clinical Trials Access 45

Veriheal

MAY 3, 2022

a necessary question to address as medical marijuana becomes more accessible. Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. Missing Information. Daily Cannabis Use as a Disqualifier.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

AUGUST 12, 2021

11, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business. LONDON, Aug. Business highlights.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

CannaMD

MARCH 8, 2020

In January of 2020, the Journal of the American College of Cardiology published a review titled Marijuana Use in Patients With Cardiovascular Disease. Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. Marijuana users with cardiovascular disease.

Patients 79

Patients Marijuana Research and Development Clinical Trials 79

Project CBD

NOVEMBER 11, 2023

I have many patients that want to use cannabis, and they who ask me what product should they get? Dr. Weil: Yes, first of all, there’s been a big demand for information about cannabis from our Fellows, the people in our programs, they want to learn about it. NM: Is cannabis as medicine taught in the curriculum?

Medicine 301

Medicine Research and Development Pharmaceutical Cannabis 301

Cannabis Law Report

OCTOBER 22, 2021

s MHRA Innovation Passport provides us with access to specialist advice throughout the drug development process and has the potential to enable a speedier, more efficient development process for SPL026, the lead candidate in our psychedelic-assisted therapy approach for the treatment of MDD. For further information contact: .

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. European Regulatory Lead Executive Summary.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

OCTOBER 2, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable, and accessible work environment. European Regulatory Lead Executive Summary. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

NOVEMBER 7, 2019

Cannatrek’s Seed to Patient business model combines cutting edge cultivation expertise and world class manufacturing practices to deliver high quality medicinal cannabis oil formulations and medicinal strains of dried flowers at a significantly lower cost to patients and retailers.

Medicine 40

Medicine Patients Research and Development Clinical Trials 40

Project CBD

MAY 3, 2023

Dr. Goldstein has treated thousands of patients with medical cannabis. She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. I have used it in some of my patients with autism. But we may be on the cusp of having those trials, which would be very exciting.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

APRIL 2, 2022

Upon signing a definitive agreement, Bienstar will have access to a broad patient base in Brazil-the largest market in Latin America with 215 million people. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites.

Clinical Trials 52

Clinical Trials Research and Development Medicine Therapy 52

SpeedWeed

SEPTEMBER 17, 2021

Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. The millions of people afflicted with PTSD may soon have access to MDMA therapy, and we believe the millions suffering from TBI may experience similar relief in the future.”.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). Petition for Review.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

APRIL 13, 2022

Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Hosting clinical trials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah ).

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

NORML

SEPTEMBER 20, 2019

Essentially, the federal government has monopolized cannabis research, and ElSohly’s product, according to some scientists who’ve seen it, is unsuitable for clinical trials. For more information on this situation, see NORML Deputy Director Paul Armentano’s op-ed here. “It needs FDA approval.”

DEA 231

DEA Research and Development Clinical Trials Patients 231

Veriheal

SEPTEMBER 6, 2022

Let’s take a deeper look at how cannabis might help you catch some much-needed z’s, and hear one patient’s perspective on chasing a good night’s sleep. Current Research and a Patient’s Perspective. Clinical trials and placebo-controlled studies are needed to confirm the findings found in this review.

Sleep 105

Sleep THC CBD Chronic Pain 105

Cannabis Law Report

NOVEMBER 16, 2019

Current barriers to patient access to medicinal cannabis in Australia. On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

Cannabis Law Report

NOVEMBER 22, 2019

. “As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. 561-627-9455. 917-562-9610.

DEA 66

DEA Clinical Trials THC Research and Development 66

Veriheal

APRIL 11, 2022

You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

The Cannigma

APRIL 12, 2023

Sleep is not often the focus of clinical trials on cannabis; rather it is often a secondary outcome. This direct access to consumers allows MoreBetter to conduct informal studies, collecting data from a set of participants with a selected product over a set amount of time. Has CBN been proven to help with sleep?

Sleep 133

Sleep Data Tincture Research and Development 133